Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation | Zendy

Stacey Knight | Zendy; Raymond O. McCubrey | Zendy; Žhong Yuan | Zendy; Scott C. Woller | Zendy; Benjamin D. Horne | Zendy; T. Jared Bunch | Zendy; Viet T. Le | Zendy; Roger M. Mills | Zendy; Joseph B. Muhlestein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Adverse cardiovascular events in acute coronary syndrome with indications for anticoagulation

Author(s) -

Stacey Knight,

Raymond O. McCubrey,

Žhong Yuan,

Scott C. Woller,

Benjamin D. Horne,

T. Jared Bunch,

Viet T. Le,

Roger M. Mills,

Joseph B. Muhlestein

Publication year - 2016

Publication title -

therapeutic advances in cardiovascular disease

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.164

H-Index - 33

eISSN - 1753-9455

pISSN - 1753-9447

DOI - 10.1177/1753944716634563

Subject(s) - medicine , mace , acute coronary syndrome , hazard ratio , cardiology , myocardial infarction , unstable angina , heart failure , atrial fibrillation , antithrombotic , stroke (engine) , confidence interval , percutaneous coronary intervention , mechanical engineering , engineering

Randomized acute coronary syndrome (ACS) trials testing various antithrombotic (AT) regimens have largely excluded patients with coexisting conditions and indications for anticoagulation (AC). The purpose of this study is to examine the 2-year clinical outcomes of patients with ACS with indication for AC due to venous thromboembolism (VTE) during hospitalization for the ACS event or a prior or new diagnosis of atrial fibrillation (AF) with a CHADS2 (Congestive heart failure; Hypertension; Age; Diabetes; previous ischemic Stroke) score ⩾2.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research